Psychopharmacology Bulletin
July 8, 2024
Justin Faden, Leslie Citrome
29 citations
Since the last edition of the Black Book, several innovative agents have been approved or are poised to be approved in the coming year. These include novel antidepressants, the first muscarine agonist for the treatment of schizophrenia, the first psychedelic which may be approved for the treatment of PTSD (Post Traumatic Stress Disorder), and the first disease modifying drug for the treatment...
npj Mental Health Research
July 2, 2024
Ronit Kishon, Nadav Liam Modlin, Yael M. Cycowicz et al.
22 citations
Pre-prohibition psychedelic research with complex psychiatric patients generated a wealth of treatment methodologies and practices, providing invaluable clinical insights pertaining to the medical administration of psychedelics in various mental health diagnoses. Building upon these early studies, which lack the rigor and research tools available today, contemporary psychedelic research has...
Journal of Humanistic Psychology
July 1, 2024
Paul Grof
As humanity has been utilizing psychedelic substances for millennia, much knowledge has already been accumulated about the exploratory potential and therapeutic power of the psychedelic-induced nonordinary states of consciousness (NSC). However, we still have only a limited understanding of the process that unfolds in mind and the brain. Only recently have systematic investigations become...
JAMA Network Open
July 1, 2024
Leor Roseman, David Erritzøe, David Nutt et al.
12 citations
This quality improvement study investigates the association of interruptions during psychedelic therapy with ratings of intensity of experience.
Current Opinion in Psychiatry
July 1, 2024
Stephen N. Xenakis, Scott Shannon
5 citations
The pace of psychedelic treatments continues to increase. Regulation and coherent clinical guidance have not been established. A philosophical divide limits effective resolution of a practice delivery quandary: is this primarily a pharmacological or psychotherapeutic intervention? Lykos (formerly MAPS) has submitted its new drug application (NDA) request to the FDA for...
Journal of Psychedelic Studies
June 21, 2024
Caroline Griffin, Alec Knight
3 citations
AbstractBackground and aimsPsychedelics show promise for treatment of mental health conditions (MHCs). But there is relatively little research on indigenous psychedelics conducted in the Global South (GS). Much research is carried out in the Global North, where there are different cultural perceptions of mental health and psychedelics. Therefore, this paper appraises research on psychedelics...
Journal of Clinical Investigation
June 17, 2024
Alejandro Torrado Pacheco, Bita Moghaddam
3 citations
Psilocybin, MDMA, and ketamine have emerged as potentially effective treatments for rapid amelioration of the symptoms of mood and related psychiatric disorders. All clinical data collected so far with regard to psilocybin or MDMA, which have reported positive outcomes for treating depression, anxiety, posttraumatic stress disorder, and drug or alcohol use disorders, have involved...
International Review of Psychiatry
June 12, 2024
Daniel Villiger
20 citations
Personal psychedelic experience is common among psychedelic therapists and often considered to be a necessary aspect of training: only personal psychedelic experience allows psychedelic therapists to properly guide patients through their own psychedelic experience, to truly understand that experience, and to help them integrate it into their lives. But is this really true? The present paper...
Frontiers in Psychiatry
June 4, 2024
Julia Bornemann, James B. Close, Kirran Ahmad et al.
11 citations
Background Chronic pain is a leading cause of disability worldwide. Fibromyalgia is a particularly debilitating form of widespread chronic pain. Fibromyalgia remains poorly understood, and treatment options are limited or moderately effective at best. Here, we present a protocol for a mechanistic study investigating the effects of psychedelic-assisted-therapy in a fibromyalgia population. The...
JAMA Network Open
June 3, 2024
Amy L. Mcguire, I Glenn Cohen, Dominic Sisti et al.
41 citations
As government agencies around the globe contemplate approval of the first psychedelic medicines, many questions remain about their ethical integration into mainstream medical practice. To identify key ethics and policy issues related to the eventual integration of psychedelic therapies into clinical practice. From June 9 to 12, 2023, 27 individuals representing the perspectives of clinicians,...